ArticleHealth science reports2025
Robust Bayesian Model Averaging Meta-Analysis of Menstrual Disorders in COVID-19 Survivors: A Methodological Meta-Analysis Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Robust Bayesian Model Averaging Meta-Analysis of Menstrual Disorders in COVID-19 Survivors: A Methodological Meta-Analysis Study.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The COVID-19 pandemic has significantly affected public health worldwide. This study applies a novel Robust Bayesian Model Averaging-Publication Selection Model Averaging method (RoBMA-PSMA) to address publication bias for a single proportion and estimate the pooled prevalence of menstrual disorders in surviving women from SARS-CoV-2 through a meta-analysis of existing evidence. Methods: Data analysis was performed using both classical and novel RoBMA-PSMA approaches for meta-analysis. The R software 4.4.1 package "metafor" and JASP 0.18.3 software were used to conduct statistical analysis. Results: The pooled prevalence estimates via conditional ROBMA-PSMA, were: amenorrhea, 12% (95% CI: 3%-20%); intermenstrual bleeding, 17% (95% CI: 3%-31%); menstrual cycle regularity changes, 24% (95% CI: 9%-34%); menstrual duration changes, 15% (95% CI: 3%-32%); menstrual volume changes, 12% (95% CI: 2%-24%), pain related changes, 17% (95% CI: 3%-30%), and overall, 9% (95% CI: 5%-13%). Results of other classical methods, including random/fixed and trim and fill methods showed significantly different pooled effect sizes. Conclusion: Using a Robust Bayesian methodology, we found that 9%-24% of women of reproductive age experienced menstrual disorders during the COVID-19 pandemic, highlighting its significant impact on women's health. To address this, it is crucial to educate women about the pandemic's effects on menstrual health and provide support services, including counseling and access to specialized healthcare providers. The RoBMA-PSMA approach can help researchers effectively tackle publication bias and heterogeneity, offering a straightforward, data-driven method that requires minimal technical expertise, supported by a user-friendly tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.